Islet Antigen 2 Autoantibodies (IA-2A)
Autoantibodies directed against the intracellular tyrosine phosphatase-like domain of the IA-2 transmembrane neuroendocrine protein.
Standard vs. Optimal Reference RangesU/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<0.8 U/mL
General reference distribution across unselected commercial populations.
<0.5 U/mL (negative)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Targets neuroendocrine secretory vesicles within pancreatic beta cells, signaling aggressive cell-mediated immune destruction.
Differential Diagnosis
Elevated Levels (IA-2A High)
- •Active progressive Type 1 Diabetes
- •Rapid preclinical beta-cell loss in multi-antibody positive individuals
Low Levels (IA-2A Low)
- •Absence of active beta-cell destruction
- •Healthy immune state
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for IA-2A
- Targeted organ system imaging or functional dynamic testing related to neuroendocrine islet autoimmunity
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Islet Antigen 2 Autoantibodies - The New England Journal of Medicine (2021). PMID: 33990124
- [2]IA-2A Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35222901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Islet Antigen 2 Autoantibodies (IA-2A) into overall healthspan optimization.